ISRCTN78822107已完成不适用
FOllow-up and Brief Intervention of Conscripts in Lausanne, Switzerland: a single-centre randomised controlled trial
Swiss Alcohol Research Foundation (Fondation Suisse De Recherche Sur L'alcool) (Switzerland)0 个研究点目标入组 1,800 人开始时间: 2008年2月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. 19-year old males with a Swiss citizenship enrolling during the mandatory army recruitment process in the French-speaking part of Switzerland
- •2. Informed consent
- •3. Provision of a contact address
排除标准
- •Lack of informed consent and provision of contact address.
研究者
相似试验
尚未招募
不适用
Development and Testing a Counseling strategy for drug and alcohol misuse in prisons.CTRI/2022/01/039182Indian Council of Medical Research
招募中
Unknown
Research on Effective Follow-up Procedures During the Medication Period - Utilization of Tracing Report TemplateDiabetes, Constipation, Sleep disorders, Overactive bladderJPRN-UMIN000051057iigata University of Pharmacy and Applied Life Sciences480
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-NOCelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-DECelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-BECelgene Corporation525